Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip L Molyneaux

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Breathe (Sheffield, England)|January 17, 2022
Choosing pharmacotherapy for ILD in patients with connective tissue diseaseZhe Wu, Philip L Molyneaux
European Respiratory Review : an Official Journal of the European Respiratory Society|July 10, 2019
The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosisRachele Invernizzi, Philip L Molyneaux
European Respiratory Review : an Official Journal of the European Respiratory Society|September 3, 2013
The role of infection in the pathogenesis of idiopathic pulmonary fibrosisPhilip L Molyneaux, Toby M Maher
Annals of Translational Medicine|July 15, 2017
The respiratory microbiome in idiopathic pulmonary fibrosisRichard J Hewitt, Philip L Molyneaux
European Respiratory Review : an Official Journal of the European Respiratory Society|March 25, 2026
Progressive pulmonary fibrosis: the importance of identification and interventionPhilip L Molyneaux, Toby M Maher
Immunology|March 21, 2020
Respiratory microbiome and epithelial interactions shape immunity in the lungsRachele Invernizzi, Clare M Lloyd, Philip L Molyneaux
Drug Design, Development and Therapy|July 3, 2013
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanibHannah V Woodcock, Philip L Molyneaux, Toby M Maher
Frontiers in Medicine|May 15, 2018
Clinical Genetics in Interstitial Lung DiseaseChad A Newton, Philip L Molyneaux, Justin M Oldham
Thorax|June 16, 2018
Review of the British Thoracic Society Winter Meeting 2017, 6-8 December 2017, London, UKAran Singanayagam, Hannah V Woodcock, Philip L Molyneaux, et al.
Expert Opinion on Therapeutic Targets|July 1, 2024
Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosisSerena Bellani, Philip L Molyneaux, Toby M Maher, et al.
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Breathe (Sheffield, England)|January 17, 2022
Choosing pharmacotherapy for ILD in patients with connective tissue diseaseZhe Wu, Philip L Molyneaux
European Respiratory Review : an Official Journal of the European Respiratory Society|July 10, 2019
The contribution of infection and the respiratory microbiome in acute exacerbations of idiopathic pulmonary fibrosisRachele Invernizzi, Philip L Molyneaux
European Respiratory Review : an Official Journal of the European Respiratory Society|September 3, 2013
The role of infection in the pathogenesis of idiopathic pulmonary fibrosisPhilip L Molyneaux, Toby M Maher
Annals of Translational Medicine|July 15, 2017
The respiratory microbiome in idiopathic pulmonary fibrosisRichard J Hewitt, Philip L Molyneaux
European Respiratory Review : an Official Journal of the European Respiratory Society|March 25, 2026
Progressive pulmonary fibrosis: the importance of identification and interventionPhilip L Molyneaux, Toby M Maher
Immunology|March 21, 2020
Respiratory microbiome and epithelial interactions shape immunity in the lungsRachele Invernizzi, Clare M Lloyd, Philip L Molyneaux
Drug Design, Development and Therapy|July 3, 2013
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanibHannah V Woodcock, Philip L Molyneaux, Toby M Maher
Frontiers in Medicine|May 15, 2018
Clinical Genetics in Interstitial Lung DiseaseChad A Newton, Philip L Molyneaux, Justin M Oldham
Thorax|June 16, 2018
Review of the British Thoracic Society Winter Meeting 2017, 6-8 December 2017, London, UKAran Singanayagam, Hannah V Woodcock, Philip L Molyneaux, et al.
Expert Opinion on Therapeutic Targets|July 1, 2024
Potential of αvβ6 and αvβ1 integrin inhibition for treatment of idiopathic pulmonary fibrosisSerena Bellani, Philip L Molyneaux, Toby M Maher, et al.
Pageof 15